3-2018

The rare and the unexpected; Miller Fisher Syndrome

Saad Waheed
Ayub Teaching Hospital, Abbottabad.

Jawad Hussian
Ayub Teaching Hospital, Abbottabad.

Aqsa Shehzadi
Ayub Teaching Hospital, Abbottabad.

Follow this and additional works at: https://ecommons.aku.edu/pjns

Part of the Neurology Commons

Recommended Citation
Available at: https://ecommons.aku.edu/pjns/vol13/iss1/7
The rare and the unexpected; Miller Fisher Syndrome

Saad Waheed¹, Jawad Hussian¹, Aqsa shehzadi²
¹Department of Internal Medicine
²Ayub Teaching Hospital, Abbottabad.

Corresponding to:  Saad Waheed, Email:khana726@gmail.com

Date of submission: August 13, 2017  Date of revision: November 03, 2017  Date of acceptance: November 25, 2017

ABSTRACT:
Miller Fisher Syndrome (MFS) is a rare variant of Guillain-Barré syndrome (GBS) which is an idiopathic neuromuscular paralysis. It is considered as autoimmune disease because there are antibodies which attack the nerve cell fibers resulting in paralysis of muscles. This disease exhibits a classic clinical triad of ataxia, areflexia, and ophthalmoplegia whereas it could have more neurological symptoms. Basically it is diagnosed clinically but have a serological test for its confirmation i.e. anti-GQ1b antibody levels. Here, we report a stereotypical case of MFS with all of its cardinal symptoms with addition of some other symptoms like diplopia, ptosis of an eye and unilateral facial nerve palsy. This patient presented with all of these signs and symptoms preceded by an upper respiratory tract illness. The suspected diagnosis was aided with its serological marker anti-GQ1b antibody levels and nerve conduction studies (NCS)/electromyographic (EMG) studies and the patient was successfully treated with multiple sessions of plasmapheresis and reduction in severity of the disease was noticed.

KEYWORDS:
Miller Fisher Syndrome (MFS), Guillain-Barré syndrome (GBS), anti-GQ1b ganglioside antibodies (anti-GQ1b antibody), Upper respiratory tract illness (URTI), nerve conduction studies (NCS).

INTRODUCTION:
In 1932, James Collier was the first person to acknowledge this disease but later on it was named after Charles Miller Fisher (Canadian neurologist) who reported 3 cases in 1956. This rare variant of GBS, is only noticed in about 1-5% of all cases of GBS in Western regions of world. MFS symptoms usually begins within 1-2 weeks after a respiratory infection similarly to GBS with rapid evolution of its cardinal triad i.e. ataxia, areflexia, and ophthalmoplegia. The pivotal dissimilarity between MFS and other common variants of GBS is that the cranial nerves are affected first resulting in weakness of muscles within or surrounding the eye with poor balance & clumsy swaying walk. While, paralysis in other forms of GBS typically initiate in the legs. Here, we discuss a case of young woman with likely MFS mingling with some my as the niagreaves’ presentation symptoms.

CASE REPORT:
A 38 years old female, married and working as a teacher presented to us with complains of double vision, drooping of left eyelid & difficulty in walking for the last 2 weeks.

These symptoms were progressive in nature & were accelerating each day. All this started after an upper respiratory tract illness which was almost 10-12 days prior to the onset of these presenting complains. The symptoms were vague at the beginning but with time they were becoming more prominent in nature and paresthesias in both upper limbs along with an ophthalmoplegia had developed in the next few days. She had no significant past medical and surgical history. She did not complain of any bowel or urinary incontinence. Her personal history was normal with good appetite and did not have any smoking or alcohol intake history. In her family none was diagnosed and treated for any neurological diseases. She denied of taking any allopathic and herbal medicine except for her URTI (fluoroquinolones) in the recent past. On physical examination her vitals were in normal range and she was oriented in time place and person. Her facial examination revealed that there was ptosis in left eye, could not look up and was unable to show teeth especially, left side of face. Later on in the next 1-2 day, she also had
MFS usually presents with its cardinal triad of signs/symptoms (ophthalmoplegia, ataxia, areflexia). The less frequent complaints associated with MFS are urinary disturbances, facial and pupillary palsies, dysesthesias of limbs and mild motor weaknesses. URTI is the most common preceded event in majority of the cases of GBS and MFS (55-76%). Moreover, the frequently involved pathogens for this ailment are Campylobacter jejuni and Haemophilus influenzae.

Mostly, ophthalmoplegia is the first presenting symptom in a patient and it can be easily differentiated from other chronic diseases like myasthenia gravis and myotonic dystrophy because of its early onset of symptoms. The body weakness in MFS shows a descending pattern when compared to GBS (ascending paralysis) and along with eye problems (ophthalmoplegia, diplopia) which is also very uncommon in latter. Areflexia, can be present in several other conditions like metabolic abnormalities (hypomagnesemia, use of medication like antidepressants), diabetes, vitamin b12 deficiency and lower motor neuron diseases. In our patient there was no history of any chronic disease, trauma or any use of drugs and all lab investigations were within normal limits except of mild leucocytosis and thrombocytosis.

Heavy metal work up was not needed firstly, as patient is a teacher so exposure to any heavy metals is very less likely (also gave no history) & secondly ophthalmoplegia is not present in metal poisonings only peripheral neuropathies occurs mostly in it.

Multiple sclerosis was the first thing to be ruled out as MRI brain was absolutely normal (following the McDonald's criteria) thus omitting the need of lumbar puncture for oligoclonal bands in CSF. A diagnosis of MFS can be made with proper history, clinical examination, focusing on the triad of symptoms, with normal metabolic panel and inconclusive or normal studies of CT/MRI. EMG should be done to differentiate it from myasthenia gravis. The anti-GQ1b ganglioside antibodies level is the most sensitive serological test and it can be raised in 90% of the patients having MFS and completely negative in normal population. This antibody level is not specific for MFS but it could be present in “anti-GQ1b antibody syndrome” known for both central and peripheral nervous system deficits.

Treatment for MFS is same as it is for GBS i.e. IVIG or plasmapheresis. Our patient had 5 sessions of plasmapheresis on alternate days after which her symptoms were resolved to almost 50% of the presenting ones (ophthalmoplegia & gait much improved).

Ataxia or wobbly gait and ophthalmoplegia mostly resolve within 1-3 months of time period but complete recovery is forecasted within 6 months. Complications are rare but it could result in respiratory failure or cardiac arrhythmias or cardio pulmonary arrest.

DISCUSSION:
Miller Fisher Syndrome (MFS) is a rare disease accounting more in male population than women by a ratio of approximately 2:1. It is documented in wide range of ages but more commonly found in between 13 & 78 years.
CONCLUSION:
Although, it is very uncommon disease but it carries a significant place in the list of differential diagnosis of ataxia & ophthalmoplegia. This disease should be kept in mind of a clinician because the vague presentation of it makes difficult to diagnose or can be confused with other diseases. Thus, the prognosis of MFS is very good irrespective of severity of symptoms and patients return to their normal life by 6th month of the onset of disease.

REFERENCES:


Conflict of interest: Author declares no conflict of interest.
Funding disclosure: Nil

Author’s contribution:
Saad Waheed; concept, data collection, data analysis, manuscript writing, manuscript review
Jawad Hussain; concept, data collection, data analysis, manuscript writing, manuscript review
Aqsa Shehzadi; concept, data collection, data analysis, manuscript writing, manuscript review